Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205488 · ClinicalTrials.gov registry record · Phase 2
Nilotinib in Parkinson's Disease
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT03205488 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 76 participants.
The verdict
NCT03205488, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This study will assess the safety and tolerability of daily oral administration of nilotinib (150-300mg once daily) in Parkinson's Disease.
Interventions
- DRUG Placebo
- DRUG Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)
- DRUG Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2019-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03205488
The ClinicalTrials.gov registry entry for NCT03205488 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03205488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03205488 about?
NCT03205488 is a clinical study titled "Nilotinib in Parkinson's Disease". This study will assess the safety and tolerability of daily oral administration of nilotinib (150-300mg once daily) in Parkinson's Disease.
What is the current status of trial NCT03205488?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2017-10-16. Estimated completion is 2019-09-28.
What interventions are being tested in trial NCT03205488?
The interventions under investigation include: Placebo (DRUG), Cohort 1:Nilotinib Oral Capsules (150mg or 300mg) (DRUG), Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1) (DRUG).
Who is sponsoring clinical trial NCT03205488?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.